UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 9, 2015

SORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

6042 Cornerstone Ct. West, Suite B San Diego, CA 92121

(Address of principal executive offices)

Registrant’s telephone number, including area code: (858) 210-3700

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Delaware 001-36150 33-0344842(State or other jurisdiction

of incorporation or organization) (Commission File Number)

IRS Employer Identification No.)

� Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

� Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

� Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

� Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Sorrento Therapeutics, Inc. intends to conduct meetings with third parties in which its corporate slide presentation will be presented. A copy of the presentation materials is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

99.1 Sorrento Therapeutics, Inc. Corporate Presentation

Item 8.01 Other Events.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 9, 2015

SORRENTO THERAPEUTICS, INC.

By: /s/ Henry JiName: Henry JiTitle: President and Chief Executive Officer

Next-G

enerationC

ancer Therapeutics

February 2015

Exh

ibit 99.1

2

Safe H

arbo

r Statem

ent N

AS

DA

Q: S

RN

E

This presentation contains "forw

ard-looking statements" as that term

is defined under the Private S

ecurities Litigation

Reform

Act of 1995 (P

SLR

A), including statem

ents regarding expectations, beliefs or intentions regarding our business,

technologies and products strategies or prospects. Such forw

ard-looking statements are characterized by future or

conditional verbs such as “may,”“w

ill,”“expect,”“intend,”

“anticipate,”“believe,”

“estimate”

and “continue”or sim

ilar

verbs. Actual results m

ay differ from those projected due to a num

ber of risks and uncertainties, including, but not

limited to, the possibility that som

e or all of the pending matters and transactions being considered by the C

ompany

may not proceed as contem

plated, as well as risks inherent in additional financing, developing and obtaining regulatory

approvals of new, com

mercially-viable and com

petitive products and product candidates, including timelines, the size of

clinical trials, sufficiency of data from those trials and the requirem

ents of the FD

A for potential approval of C

ynviloq™

andby

allotherm

attersdescribed

inthe

Com

pany'sfilings

with

theS

ecuritiesand

Exchange

Com

mission,including

the

risk factorssetforth

therein.T

hesestatem

entsare

made

basedupon

currentexpectations that are subject to risk and

uncertainty and information available to the C

ompany as of the date of this presentation. T

he Com

pany does not

undertake to update forward-looking statem

ents in this presentation to reflect actual results, changes in assumptions or

changes in other factors affecting such forward-looking inform

ation. Assum

ptions and other information that could

cause results to differ from those set forth in the forw

ard-looking information can be found in the C

ompany's filings w

ith

the Securities and E

xchange Com

mission, including its m

ost recent periodic report. We intend that all forw

ard-looking

statements be subject to the safe-harbor provisions of the P

SLR

A.

Cyto

toxics

CY

NV

ILOQ

™

Targ

eted T

herapy

MY

C inhibitor

TR

AIL m

odulator

Imm

un

oth

erapy

PD

-1, PD

-L1, CT

LA-4

Bispecific A

bs

Targ

eted T

herapy

Anti-V

EG

FR

2 AD

C

Anti-c-M

ET

AD

CB

ispecific AD

C

Ad

op

tive Cellular

Imm

un

oth

erapy

Chim

eric Antigen R

eceptor T

umor-attacking

Neukoplast

®

(Partnership w

ith Conkw

est)

RT

X

Intractable C

ancer Pain

A C

om

preh

ensive O

nco

log

y Co

mp

any

Deep

and

Co

mp

lemen

tary Pip

eline C

reates Sig

nifican

t Op

po

rtun

ities-N

ovel b

reakthro

ug

h co

mb

inatio

n th

erapeu

tic regim

ens an

d m

od

alities to attack can

cerS

i gn

ificant red

uctio

n in

clinical d

evelop

men

t costs an

d tim

eline

Si g

nifican

t com

mercial ed

ge in

futu

re dru

g p

ricing

CY

NV

ILOQ

, CA

R.T

NK

, CA

R.T

NK

(Chim

eric Antigen R

eceptor Tum

or-attacking Neukoplast) are tradem

arks owned by S

orrento Therapeutics, Inc.

Neukoplast is a tradem

ark owned by C

onkwest, Inc.

Sm

allM

olecu

les B

iologics

Cell

Th

erapyS

up

portive

Care

3

4

Co

rpo

rate Even

ts Valid

ate and

Ad

vance S

orren

toP

i pelin

e Un

lockin

g S

ign

ificant V

alue

“Th

e Im

mu

no

therapy

An

tibo

dy

Co

mp

any”

Exclusive global partnership w

ith Conkw

est to develop next generation anti-cancer cellula r

imm

unotherapyw

ith"O

ff-the-Shelf"

CA

R.T

NK

™(C

himeric

Antigen

Receptor

Tum

or-attackingN

euKoplast)

First joint venture w

ith NantW

orks and Abraxis B

ioScience Inc. founder, D

r. Patrick S

oon-S

hiong,to develop next generation im

munotherapies for the treatm

ent of cancer andautoim

mune disease.

G-M

AB

AD

C

Licensing agreement to develop and com

mercialize anti-P

D-L1 m

Ab w

ith Lee’s P

harmaceutical for greater C

hinese Market

Exclusive research and option a greem

ent to generate and develop antibody-drug conjugates (A

DC

s) with M

orphotek / Eisai

CY

NV

ILO

Q

Patient enrollm

ent in TR

IBE

CA

registration trial completed. P

ilot PK

suggestsbioequivalence (B

E) betw

een Cynviloq and album

in-bound paclitaxel

CA

RT

NK

Deep

and

Co

mp

lemen

tary Pip

eline C

reates S

i gn

ificant O

pp

ortu

nities

*T

RIB

EC

A505

(b)(2

)B

ioequivalencetrialversus

albumin-bound

paclitaxel(A

braxane®

)(p

aclitaxelalbumin-bound

particlesfor

injectable

suspension)(album

in-bound

), Abraxane®

is a registered tra

demark of and m

arketed by C

elgene Corp

.P

DL1.T

NK

,CD

123.TN

K,R

OR

1.T

NK

,PS

MA

.TN

Kare

trademarks

owned

byS

orrentoT

herapeutics,Inc.

CY

NV

ILOQ

™

G-M

AB

Bi-S

pecific Ab

RT

X

Imm

uno-oncology>

PD

-L1, PD

1, CD

47, CD

137

VE

GF

R2, c-M

ET

, CX

CR

5

Intractable Cancer P

ain

IND

ICA

TIO

N>

TA

RG

ET

Metastatic B

reast Cancer

Non-S

mall C

ell Lung Cancer

T R

I B E

C A

*R

egistration trial completed

PH

AS

E 3

PH

AS

E 2

PH

AS

E 1

PR

EC

LINIC

AL

Solid tum

ors and hematological m

alignancies

AD

C

MY

C Inhibito r

PD

-L1.TN

K, C

D123.T

NK

, RO

R1.T

NK

, PS

MA

.TN

K

PD

-L1/c-ME

T; P

D-L1/C

TLA

-4, PD

-L1/EG

FR

5

6

Lead

On

colo

gy P

rod

uct O

pp

ortu

nity

Cynviloq

Registration

Trial

(Paclitaxel p

olym

ericm

icelle)

7

Mean

size~25 n

m

Cyn

viloq

paclitaxel pol ym

eric micelle

Ch

emicalpolym

er: P

ol y-lactide and pol yethylene glycol diblock copol ym

er

3>300

mg

/m2

(up

to435

mg

/m )

Alb

um

in-b

ou

nd

p

aclitaxelM

ean size

130 nm

Bio

log

icalpolymer:

Donor-derived hum

an serum

albumin (H

SA

)2

260m

g/m

2

Taxo

l ®

paclitaxel

Crem

op

ho

rEL

excipient:P

ol yoxyethylated castor oil

Fo

rmu

lation

Gen

eration

1175

mg

/m2

Maxim

um

To

lerated D

ose

Peak

Pro

du

ct Sales

~ $1.6B

(WW

in 2000)

$ 2.2 B* (2020)

MB

C, N

SC

LC, P

C

Conversion of

paclitaxel sales +new

indications

*Celgene P

resentation at JPM

Healthcare C

onference Jan 2015

Cyn

viloq

: Next G

eneratio

n P

aclitaxel Th

erapy

2

st

ndrd

8

Cyn

viloq

Clin

ical Develo

pm

ent S

um

mary

Ph

ase 1:T

rialsestablished

MT

Dat

>300

mg/m

2-

Dana

Farber

Cancer

Inst,R

ussia,&

S.K

orea(total n=

80)

>300

mg/m

2(q

3w)

vs.175

mg/m

2(T

axol;w

eekly)

Ph

ase 2:C

ompleted

trialsin

MB

C,

NS

CLC

,P

C,

OC

,BC

;in

US

-Y

aleC

ancerC

enter,R

ussia,S

.K

orea(totaln=259)

Possible P

hase 3

sND

A p

rograms in these

tumor types

Ph

ase 2b*:C

hemo-naïve S

tage IIIb/IV N

SC

LC vs T

axol in S. K

orea (total n=276; Cynviloq n=

140)

230m

g/m²+

cis(q

3w)

vs.Taxol175

mg/m

2+

cis;non

-inferiority

established

Ph

ase 2*:1st line treatm

ent of OC

vs Taxol in S

. Korea (total n=

100; Cynviloq n=

50)

260m

g/m2

+carbo

(q3w

)vs.T

axol175m

g/m2

+carbo;

non-in

feriorityestablished

Ph

ase 3:M

BC

in S. K

orea (total n=209; C

ynviloq n=105 vs Taxol n=104)

GP

MB

C301.

An

Open-labe

l,Random

ized,Para

llel,Phase

3T

rialtoE

valuatethe

Efficacy

andS

afetyofC

ynviloqcom

paredto

Genexol®

(Paclita

xel with C

remophor E

L) in Su

bjects with R

ecurrent or M

etastatic B

reast Cance

r)

PM

-Safety:

Com

pleted for MB

C and N

SC

LC (total n=

502)

Efficacy and safety data supportive of 505(b)(2) subm

ission

Total num

ber of patients across all trials: 1,260

Data

on file; * Investigator Initiated Stu

dy

9

Co

mp

arative Ph

ase 3 MB

C C

linical R

esults

* Trieu

etal.2013.IG

-001for

Metastatic

Brea

stCancer-Interim

Analysis

ofaP

hase3

Trial.4

Nanom

edicineC

onference,Sydney,A

ustralia.** G

radishar et al. 2005. J C

lin Onco

l, 23:7794-7803.

*** Gu

an et al. 2007. A

SC

O A

nnual Meetin

g Proceedings P

art I. Jun 20;25 (Suppl 1

8):1038.

Overall

Response

Rate (%

)

th

10

Bio

equ

ivalence = A

ccelerated P

athw

ay to M

arket

T R

I B E

C A

™

Album

in-boundpaclitaxel(n =

27)*

Cynviloq

(n = 27)*

Cynviloq

Album

in-bound paclitaxel

Key P

arameters:

Cycle 1

Cycle 2

-P

atients with M

BC

No

te:P

revioustrialsize

estimate

of100

patientsw

asbased

onP

Ksim

ulatio

nofalbum

in-boundpaclitaxel

andC

ynviloqh

istorical

data

with

bo

thd

rug

sg

ivenat

differen

td

oses

and

infu

sion

rates.

Based

onthe

recentpositive

initialP

Kdata

andsub ject

toF

DA

guidance,53

patientsm

aybe

sufficientto

establishB

E.

TR

IB

EC

A™

(TR

Ialestablishing

BioE

quivalencebetw

eenC

ynviloq™and

Album

in-boundpaclitaxel)

isa

trademark

owned

byS

orrentoT

herapeutics,Inc. •

Dose:

260m

g/m

2

•Infusion tim

e: 30 min

•D

uration: 3 weeks +

crossover for 3 w

eeks•

Endpoints:

AU

Cand

Cm

ax

(90% C

I)

(TR

Ial establishing BioE

quivalence between C

ynviloq™ and A

lbumin-bound paclitaxel)

11

Pilo

t PK

Data A

nalyses S

ug

gest

BE

vs.Alb

um

in-B

ou

nd

Paclitaxel

Param

etersR

atio o

f Cyn

viloq/

Albu

min

-bo

un

d p

aclitaxel (%

)90%

CI

Ln(AU

C0 to )

109.193.98 –

126.58

Ln(Cm

ax )102.5

83.10 –126.35

Point estim

ate110

-Ln(A

UC

0to

)N

= 53 with 90%

power

BE

Assessm

ent an

d S

amp

le Size E

stimate

Lo

g -linear P

lot (n

=8)

12

TR

IBE

CA

Patient E

nrollment C

ompleted

54 pts

Patien

ts from

recruited

from

sites in E

ast Eu

rop

e, US

A an

d A

siaT

otal 111 p

atients enrolled

(expan

ded safety d

ata)In

itial repo

rted AE

s con

sistent w

ith histo

rical nab

-paclitaxel to

xicity pro

file

Estim

ated T

imelin

e and

Next S

teps*

First patient dosed: M

arch 31,

2014

Last patient in: Janu

ary 2015

ND

A filin g:

Q3

2015

Product launch (M

BC

and NS

CLC

):2016

BE

S

tud

y

2014

2015

ND

A

Filin

g2016

FD

A

Ap

pro

val

LA

UN

CH

2016

*Estim

ates, subject to discussions with the F

DA

.

14

IntractableC

ancerP

ain

Resin

iferatoxin

(RT

X): A

No

vel, No

n-o

piate A

nalg

esic

RT

X

15

Intrag

ang

lion

ic:

injectioninto

or near the dorsal root ganglio n

Intrath

ecal:injection

intothe

cerebrospinal fluid spac e

Tw

o In

jection

Sites =

Tw

o P

rod

ucts fo

r Hu

man

Use

Cro

ss Sectio

ns o

f sp

inal co

rd*

Absence of T

RP

V1-

positive cells after RT

X

treatment

TR

PV

1-positive cells (dark brow

n)

* Adapted from

Karai et al., 2004

Dorsal root ganglion

16

Su

mm

ary of In

terim D

ata from

the P

hase 1/2 N

IHS

po

nso

red T

rial

No unexpected

toxicitiesA

ll 6 patients had nearcom

plete relief post-in jection

100% of non-am

bulatory patients could w

alk postin jection (n=

2)

MT

D not reached,

additional dose optim

ization being explored

RE

SU

LT

S

Clinically m

eaningful im

provement in Q

OL

Improved pain scores w

ithincreased activit y

DE

SIG

N O

VE

RV

IEW

6 advanced cancer patients with severe refractory pain received a single injection of R

TX

.N

europathicpain,

visceralandbone

pain2

oto

bonem

etastases(49-61 years; 4 M

/ 2F, M

BC

, H&

N, pancreatic, lym

phoma, S

CLC

, endometrial cancer).

17

Next S

teps fo

r RT

X D

evelop

men

t

~3 years for clinical developm

ent

Com

plete intractable cancer pain clinical Phase 1/2

trial (intrath

ecal injectio

n) under S

orrento IND

;n=

45-60 patients; optimization of dosin g study

End of P

hase 2 meeting w

ith FD

A (for in

trathecal in

jection

)

Initiate Phase 3 (in

trathecal in

jection

)

Phase 1/2 trial(s) (in

tra gan

glio

nic in

jection

)

End of P

hase 2 meetin g w

ith FD

A (for in

tragan

glio

nic in

jection

)

OB

JEC

TIV

ES

for 2015 and 2016

18

Imm

un

oth

erapy P

rog

rams

G-M

AB

+ Neu

kop

last

+ Pro

prietar y T

oxin

s &C

on

jug

ation

Ch

emistries

19

G-M

AB

: Lib

rary of T

herap

eutic A

ntib

od

ies

Hig

h V

alue O

nco

log

y Targ

ets: Im

mune

modulation:P

D-1,P

D-L1,C

D47

Antibody

Drug

Conjugates:V

EG

FR

2,c-Met

Size of T

arget Antigen

Pro

prietary tech

no

log

y:

RN

A am

plification used for librar ygeneration

Freedom

-To-O

perate

Ver y h

igh

library d

iversity: 2.1

x10

16distinctantibodies

Fu

ll y hu

man

antib

od

ies

Hig

h su

ccessful screen

ing h

it rate(over 70 tar gets screened)

Ideal fo

r CA

R-G

eneratio

n

Difficu

lt Tar g

ets: S

mall P

eptides

Mo

st Difficu

lt Targ

ets:G

Protein-C

oupled Receptors (G

PC

Rs)

No

stacking

royalties

20

An

ti-PD

-L1 m

Ab

Exh

ibits P

oten

t Activity

Imm

une Modulation*

Tum

or Mouse M

odel**

***

* mA

bs @

0.05 m

g/mL

** xeno graft m

odel using H1975 hum

an NS

CLC

cells; % inhibition relative to co

ntrol mA

b treatm

ent*** p<

0.05, m

ean tum

or volume

s are significantly reduced in S

TI-A

1010 group versus control groups as determined by M

ann-W

hitney u-test

Com

petitor mA

b

So

rrento

mA

b

Day

21

Com

petitor mA

b

So

rrento

mA

b

An

ti-PD

1 mA

b E

xhib

its Excellen

t Activity

Imm

une Modulation*

Target S

pecificity

Control

So

rrento

mA

b

Hum

anP

D1

Cyno

PD

1H

uman

CT

LA-4

Hum

anC

D28

Hum

anIC

OS

PB

Scontrol

K-L

ock

C-L

ock

C-L

ock conju

gatio

n

Enhances A

DC

stabilit y P

rolon gs PK

profileR

educes off-tar get effects

Maleim

ide

conju

gatio

n

Destabilizes antibody structure

Dru g-antibody linkage not stable

Altered P

K profile

Off-tar get drug effects

Pro

prietary K

-Lo

ck and

C-L

ock C

on

jug

ation

C

hem

istries En

able H

om

og

eneo

us A

DC

s

22

23

Pro

prietary H

igh

Po

tency D

uo

statin T

oxin

s

EC

50(p

M)

Can

cerH

er-2D

M1

MM

AE

Du

ostatin

3

SB

KR

3B

reast+++

9572

30

HC

C1954

Breast

+++124

7868

BT

474B

reast+++

818126

214

MD

A-M

B-361

Breast

+++218

15135

ZR

75B

reast+++

215298

264

HC

C1419

Breast

+++391

271332

MD

A-M

B-453

Breast

++1,877

>100,000

452

MD

A-M

B-175

Breast

+>

100,0001,348

425

N87

Gastric

+++368

139260

OE

-19G

astric+++

176164

130

SK

OV

-3O

varian+++

150251

144

Tra

stuzumab

was used as targeting m

Ab

24

VE

GF

R2-A

DC

ST

I-D0168

c-ME

T-A

DC

ST

I-D0602

In V

ivo P

roo

f-of-C

on

cept o

f So

rrento

AD

Cs

A431 squam

ous-cell carcinoma

cells; ^indicates dosingU

87 xenograft; dosing twice w

eekly; m

aytan

sinoid dru

g conjug

ates

25

“Th

e Imm

un

oth

erapy A

ntib

od

y JV C

om

pan

y”

Independent company focused

on advancing next generation imm

unotherapies against cancer and auto-im

mune diseases.

Both com

panies will contribute to its pipeline of clinical and preclinical

assets of novel and proprietar y imm

unotherapies, AD

Cs, and bispecific

antibodies.

Joint venture will draw

from N

antWorks’proteom

ic and genomic

capabilities and Sorrento’s industry-leading, highly diverse G

-MA

B library.

AN

EX

CL

US

IVE

JOIN

T P

AR

TN

ER

SH

IP

26C

AR

.TN

K is a tradem

ark owned by S

orrento Therapeutics, Inc.

Neukoplast is a tradem

ark owned by C

onkwest, Inc.

Ad

vancin

g C

ellular Im

mu

no

therap

y B

e yon

d C

AR

-T C

ell Th

erapies

Neukoplast®

NK

cell line(“off-the-shelf”)

Broad anti-cancer activity in

solid

and liquid tumors

No clinical D

LTs/S

AE

s in over 40 patients treated

Advanced proteom

ics platform

Pro prietary gene insertion

(without use of lentiviruses)

‘GM

P in a B

ox’production technology

G-M

AB

27

High successful screening rate

(over 70 targets screened)

Proprietary technologies w

ith F

TO

Vast diversity hum

an antibody library

28

CA

R.T

NK

vs CA

R-T

: Key D

ifferentiato

rs

Sim

ple:

Off-the-shelf

universalproduct

CA

R-m

odified Neukoplast cells

Cell P

roduction

Transduction

characteristics100%

:M

astercellbank

with

100% of cells expressin g C

AR

MO

AB

road

:M

ultipleM

OA

s,targetingand

killin g through CA

R-dependent and

innatem

echanisms

(“off-target/

on-tumor”)

Safety

Go

od

:O

n-target/

off-tumor

effects lim

ited due to short half life and lack of IL-6 production

CO

GS

Lo

w:

largescale

bioreactor m

anufacturin g for many patients

Invasive:

Autolo gous

(patient-derived)invasive procedure/leukapheresis

Variab

le%

:V

ariableC

AR

transfection &

expression

Lim

ited:

Requires

co-stimulators

(CD

80, CD

86) not present in man y

solid tumors

Po

or:

Cytokine

releasesyndrom

e,IC

U;

Prolonged bone m

arrow suppression;

Cardiotoxicit y; R

eported cases of encephalitis; D

eath

Hig

h:

requiresindividual

patient processin g

CA

R.T

NK

CA

R-T

Un

mo

dified

Neu

kop

last Clin

ically Valid

ated In

Several

Ph

ase 1 Stu

dies

More than 40 patients treated

Advanced m

etastatic disease refractor y to chemo, biologics, cytokines,

radiation, and surgery

Many patients received m

ultiple dosing regimens (up to 6 m

onths)

Prom

ising activity against different cancer types, including acute myelogenous

leukemia (A

ML), lym

phoma (N

HL, H

L), melanom

a, renal cell cancer (RC

C), and lung

cancers (SC

LC, N

SC

LC)

No D

LTs; onl y 1 “grade 4 S

AE

”(hypoglycem

ia likely related to tumor lysis)

29

30

-5000 0

5000

10000

15000

20000

25000

30000

35000

PH

AA

llogeneic Donor

NK

-92

CP

M

Lymphocytes from

2 healthy donors co-cultured with each other

vigorous proliferation

Co-cultured w

ith Neukoplast (7 days)

no

pro

liferation

Gold: D

onor 1A

qua: Donor 2

T cell P

roliferatio

n m

easured

usin

g

Mixed

Lym

ph

ocyte R

eaction

(ML

R) C

ultu

re Assay

Neu

kop

last do

no

t stimu

late allog

eneic T

cells

Neukoplast

PH

AA

llogeneic Donor

31

CA

R.T

NK

: CA

R-m

od

ified N

euko

plast

Clonal cell lines expressing one or m

ore CA

Rs to establish a range of distinct products

Multiple

killingm

echanisms

-C

AR

-targetedas

wellas

broadintrinsic

anti-cancer activit y of N

eukoplast (“off-target / on-tumor”)

En gages the adaptive im

mune system

through cytokine secretion and imm

une cellrecruitm

ent

Titratable: repeat dosin g option; controllable dose exposure to m

anage safety risk

32

Serial K

illing

of H

er2+ Cells b

y Her2.T

NK

Cells

Hom

ing to Her2 expressing tum

ors

Inhibition of Her2+

RC

C m

etastasis

Selective cytotoxicity (spares norm

al cells)

Schoenfeld et al. M

ol Therapy, in press

IN V

IVO

PR

EC

LIN

ICA

L M

OU

SE

DA

TA

Grow

th inhibition and killing correlatew

ith Her2 expression levels

“Serial killing”

of Her2+

target cellseven after gam

ma radiation w

ith 10 Gy

33

Her2.T

NK

Dem

on

strate Tu

mo

r Ho

min

g an

d P

oten

t A

nti-G

liom

a Activit y in

Mice

Schoenfeld et al. M

ol Therapy, in press

Tum

or homing of C

AR

.TN

Ks

Intracranial LN-319 glioblastom

axenografts in N

SG

mice

Pro

spective C

AR

.TN

Ks fo

r Develo

pm

ent

(Initial L

ist)

Targ

etP

oten

tial Ind

ication

(s)

EG

FR

viii.TN

KG

lioma

EphA

3.TN

KG

lioma, A

ML

L1CA

M.T

NK

Gastric, pancreatic, N

SC

LC

CS

PG

4.TN

KH

&N

, breast, mesotheliom

a

BC

MA

.TN

KM

yeloma

RO

R1.T

NK

CLL, A

LL, MC

L, breast, lung, pancreas

PS

MA

or P

SC

A.T

NK

Prostate

PD

L1.TN

KM

yeloma, R

CC

, NS

CLC

, TN

BC

CS

1.TN

KM

yeloma

CD

123.TN

KA

ML

CD

19.TN

KC

LL, ALL

CD

22.TN

KC

LL, ALL

CA

R targets jointly selected by the

Steerin g C

omm

ittee

Lead company w

ill be responsible forall pre-clinical and clinical developm

ent,regulatory filings, andcom

mercialization

Profit sharing on all C

AR

.TN

Ks

revenues proportional to contribution

EG

FR

viii.TN

K, E

phA3.T

NK

, L1CA

M.T

NK

, CS

PG

4.TN

K, B

CM

A.T

NK

, RO

R1.T

NK

, PS

MA

.TN

K, P

CM

A.T

NK

, PD

L1.TN

K, C

S1.T

NK

, CD

123.TN

K, C

D19.T

NK

, CD

22.TN

K are tradem

arks owned by S

orrento Therapeutics, Inc.

34

Next S

teps fo

r CA

R.T

NK

Develo

pm

ent

H1 2015

Generation of C

AR

s

H2 2015

Generation and evaluation of stable C

AR

.TN

K cell lines

2016IN

D-enabling studies, IN

D subm

ission, and initiation of Phase 1 studies

35

36

Cyto

toxics

CY

NV

ILOQ

™

Targ

eted T

herapy

MY

C inhibitor

TR

AIL m

odulator

Imm

un

oth

erapy

PD

1, PD

-L1, CT

LA-4

Bispecific A

bs

Targ

eted T

herapy

Anti-V

EG

FR

2 AD

C

Anti-C

ME

T A

DC

Bispecific A

DC

Ad

op

tive Cellular

Imm

un

oth

erapy

Chim

eric Antigen R

eceptor T

umor-attacking

Neukoplast

®

(Partnership w

ith Conkw

est)

RT

X

Intractable C

ancer Pain

A C

om

preh

ensive O

nco

log

y Co

mp

any

Deep

and

Co

mp

lemen

tary Pip

eline C

reates Sig

nifican

t Op

po

rtun

ities-N

ovel b

reakthro

ug

h co

mb

inatio

n th

erapeu

tic regim

ens an

d m

od

alities to attack can

cerS

i gn

ificant red

uctio

n in

clinical d

evelop

men

t costs an

d tim

eline

Si g

nifican

t com

mercial ed

ge in

futu

re dru

g p

ricing

CY

NV

ILOQ

, CA

R.T

NK

, CA

R.T

NK

(Chim

eric Antigen R

eceptor Tum

or-attacking Neukoplast) are tradem

arks owned by S

orrento Therapeutics, Inc.

Neukoplast is a tradem

ark owned by C

onkwest, Inc.

Sm

allM

olecu

les B

iologics

Cell

Th

erapyS

up

portive

Care

37

Next-G

enerationC

ancer Therapeutics

Henry Ji, P

h.D.

President and C

EO

h ji@sorrentotherapeutics.com

(858) 668-6923

Geor ge U

yE

xecutive Vice P

resident and CC

Oguy@

sorrentotherapeutics.com(661) 607-4057

CO

NT

AC

T: